Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Case report of clinical improvement in a patient with neuroinvasive West Nile virus after late treatment with interferon alpha
Infectious Disease
P9 - Poster Session 9 (12:00 PM-1:00 PM)
13-017

To demonstrate the possible utility of interferon alpha as a treatment for severe West Nile neuroinvasive disease (WNND).

West Nile virus (WNV) is a mosquito borne flavivirus that can infect humans. Approximately 80% of WNV-infected patients are asymptomatic, 20% develop WN fever, and less than 1% develop WNND. Several case reports and animal model studies demonstrate improvement in clinical symptoms if used within a timely range. Here, we demonstrate a case with clinical improvement after utilization of interferon alpha therapy late in the course of illness.  

This was a 61-year old male with history of lower back pain who initially presented to an outside hospital with fall due to sudden onset bilateral lower extremity weakness and progressive urinary and bowel incontinence in the setting of fevers and chills over the past 2-3 days. An MRI t-spine showed a T2 hyperintense lesion extending from T8 to the conus. He quickly became encephalopathic as well. He was treated with a course of high dose steroids and IVIG without any improvements. He was then started on a 14-day course of interferon alpha 2b more than two weeks after initial presentation.

On day 3 of interferon alpha 2b therapy, patient began to show some clinical improvements in mental status, upper extremity weakness, and bowel incontinence. However, he continued to have bilateral lower extremity weakness and urinary incontinence.

In patients with WNND refractory to other treatments, there may be utility in treatment with a course of interferon alpha. No randomized control trial or well-documented therapeutic treatment is established for patients with WNND.  Few cases in literature reports IFN alpha was used as an experimental treatment for humans, with some intermittent success even if administered early in the course of illness. The case discussed above showed some positive clinical outcome for a patient with severe WNND.
Authors/Disclosures
Saher Suleman, MD (Dell Children's Medical Center)
PRESENTER
Dr. Suleman has nothing to disclose.
Fawaz Philip Tarzi, MD (Barrow Neurological Inst) Dr. Tarzi has nothing to disclose.